Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Cash from Investing Activities: 2019-2025

Historic Cash from Investing Activities for Keros Therapeutics (KROS) over the last 7 years, with Sep 2025 value amounting to -$132,000.

  • Keros Therapeutics' Cash from Investing Activities rose 65.80% to -$132,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year increase of 21.85%. This contributed to the annual value of -$1.9 million for FY2024, which is 21.63% up from last year.
  • Keros Therapeutics' Cash from Investing Activities amounted to -$132,000 in Q3 2025, which was up 81.67% from -$720,000 recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Cash from Investing Activities ranged from a high of -$132,000 in Q3 2025 and a low of -$1.1 million during Q1 2023.
  • Its 3-year average for Cash from Investing Activities is -$528,364, with a median of -$541,000 in 2023.
  • In the last 5 years, Keros Therapeutics' Cash from Investing Activities plummeted by 1,721.43% in 2021 and then spiked by 65.80% in 2025.
  • Over the past 5 years, Keros Therapeutics' Cash from Investing Activities (Quarterly) stood at -$159,000 in 2021, then plummeted by 120.75% to -$351,000 in 2022, then crashed by 54.13% to -$541,000 in 2023, then spiked by 46.58% to -$289,000 in 2024, then skyrocketed by 65.80% to -$132,000 in 2025.
  • Its Cash from Investing Activities stands at -$132,000 for Q3 2025, versus -$720,000 for Q2 2025 and -$565,000 for Q1 2025.